New testing system could accelerate vaccine development times

A new testing system for influenza could significantly accelerate the development of new vaccines and drugs.

The new testing system, FluiiQ, is the result of collaboration between MSD, an Australian pharmaceutical company, and Deakin University - Australia. The recently developed questionnaire is intended to provide a new means of understanding the intensity and impact of the flu that will allow scientists to assess if treatments are effective, according to

“The development and testing of vaccines and drugs designed to reduce the severity and impact of patients' flu symptoms requires people to report how they are feeling and for improvements in their health to be tracked during the course of their illness,” Deakin Professor Richard Osborne said, reports. "Companies are making large investments over many years to find a vaccine or treatment for the flu. If they cannot appropriately measure the efficacy of their potential new agents in clinical trials, then important drugs or vaccines may not move forward in development."

FluiiQ is the first attempt at creating a test that seeks to fulfill strict requirements set by regulatory bodies like the U.S. Food and Drug Administration.

The questionnaire’s development will be charted in Value in Health, the journal of the International Society for Pharmacoeconomics and Outcomes Research.